Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16759829 | 1.00 | LRRK2 (0.37) | LRRK2BTKHCRTR1HCRTR2MGLL | |
| SCHEMBL16759899 | 0.91 | FASN (0.37) | LRRK2NPC1HPGD | |
| SCHEMBL22911080 | 0.91 | FASN (0.37) | LRRK2NPC1HPGD | |
| SCHEMBL22911089 | 0.91 | HCRTR1 (0.34) | LRRK2BTKHCRTR1HCRTR2MGLL | |
| SCHEMBL22910861 | 0.90 | HPGD (0.36) | LRRK2BTKHCRTR1HCRTR2MGLL | |
| SCHEMBL16759843 | 0.90 | HPGD (0.36) | LRRK2BTKHCRTR1HCRTR2MGLL | |
| SCHEMBL16759886 | 0.90 | ATXN2 (0.39) | MGLL | |
| SCHEMBL22911078 | 0.90 | ATXN2 (0.39) | MGLL | |
| SCHEMBL16759935 | 0.89 | ATXN2 (0.36) | MGLLHPGD | |
| SCHEMBL22910880 | 0.89 | ATXN2 (0.36) | MGLLHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | NPY1R, NPY2R, DECR1 | LRRK2 3273/4885BTK 2665/4885HCRTR1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.